Skip to Main Content

Paper Details

A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3Kα inhibition in controlling tumor growth.
Int J Cancer
18
2019
28-cell line panel, AKT, AKT1, CSMD1, EGFR, HNSCC, HNSCC patient-derived xenografts, HNSCC tumors, HNSCC xenografts, HNSCCs, Head and neck squamous cell carcinomas, PDX, PDX models, PI3K, PIK3CA, PIK3CA gene, PIK3CA mutations, cell lines, mTOR, patient, patients, tumor
Adult, Aged, Animals, Carcinoma, Squamous Cell, Cell Line, Tumor, Cetuximab, Class I Phosphatidylinositol 3-Kinases, Female, Head and Neck Neoplasms, Humans, Male, Mice, Inbred NOD, Mice, Knockout, Mice, SCID, Middle Aged, Mutation, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-akt, Signal Transduction, TOR Serine-Threonine Kinases, Tumor Burden, Xenograft Model Antitumor Assays
Author NameAffiliation
Kara M RuicciWestern University
Kara M RuicciWestern University
Jalna MeensPrincess Margaret Cancer Centre, University Health Network
Ren X SunOntario Institute for Cancer Research
Ren X SunUniversity of Toronto
Giananthony RizzoWestern University
Nicole PintoWestern University
John YooWestern University
John YooWestern University
Kevin FungWestern University
Kevin FungWestern University
Stephanie Danielle MacNeilWestern University
Stephanie Danielle MacNeilWestern University
Joe S MymrykWestern University
Joe S MymrykWestern University
Joe S MymrykWestern University
John W BarrettWestern University
Paul C BoutrosOntario Institute for Cancer Research
Paul C BoutrosUniversity of Toronto
Paul C BoutrosUniversity of Toronto
Laurie AillesPrincess Margaret Cancer Centre, University Health Network
Laurie AillesOntario Institute for Cancer Research
Laurie AillesUniversity of Toronto
Anthony C NicholsWestern University
Anthony C NicholsWestern University
Anthony C NicholsWestern University
  • 1 - 26

Datasets

Release 1.2